M. Polée

2.1k citations

13 papers · 330 indexed · h-index 8

Impact in

Pulmonary and Respiratory Medicine top 10%
- Gastric Cancer Management and Outcomes
- Lung Cancer Treatments and Mutations
- Prostate Cancer Treatment and Research
Surgery
- Esophageal Cancer Research and Treatment
- Esophageal and GI Pathology

Papers in ⓘ

Pulmonary and Respiratory Medicine 9
- Gastric Cancer Management and Outcomes 7
- Prostate Cancer Treatment and Research 2
- Lung Cancer Treatments and Mutations 2
Otorhinolaryngology 1

Co-authors: G. Stoter (5 shared papers)Ate van der Gaast (5 shared papers)Peter D. Siersema (4 shared papers)Ted A.W. Splinter (3 shared papers)M.E.L. van der Burg (3 shared papers)Ferry A.L.M. Eskens (2 shared papers)T.C. Kok (2 shared papers)H.W. Tilanus (3 shared papers)
Journals: Journal of Clinical Oncology (3 papers)Annals of Oncology (3 papers)European Journal of Cancer (3 papers)British Journal of Cancer (2 papers)Anti-Cancer Drugs (1 paper)
Partner nations: Netherlands United States Norway

In The Last Decade

M. Polée

13 papers receiving 329 citations

Peers

Countries citing papers authored by M. Polée

Since Specialization

Citations

This map shows the geographic impact of M. Polée's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Polée with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Polée more than expected).

Fields of papers citing papers by M. Polée

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Polée. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Polée. The network helps show where M. Polée may publish in the future.

Co-authors

The 25 scholars most cited alongside M. Polée, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with M. Polée Line = papers co-authored together M. Polée links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work
1	Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy British Journal of Cancer ·M. Polée, Wim C.J. Hop, T.C. Kok, Ferry A.L.M. Eskens, M.E.L. van der Burg, Ted A.W. Splinter, Peter D. Siersema, Hugo W. Tilanus, G. Stoter, Ate van der Gaast	2003	81
2	Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer British Journal of Cancer ·M. Polée, Ferry A.L.M. Eskens, M.E.L. van der Burg, Ted A.W. Splinter, Peter D. Siersema, H.W. Tilanus, Jaap Verweij, G. Stoter, Ate van der Gaast	2002	63
3	Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group Annals of Oncology ·Johannes J.M. Kwakman, Lieke H. J. Simkens, Johan M. van Rooijen, Agnès J. van de Wouw, Albert J. ten Tije, G.J. Creemers, Mathijs P. Hendriks, Maartje Los, R J van Alphen, M. Polée, E.W. Muller, Ankie M.T. van der Velden, Theo van Voorthuizen, Miriam Koopman, Linda Mol, Erik van Werkhoven, Cornelis J.A. Punt	2017	47
4	A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study Annals of Oncology ·A.K.L. Reyners, Linda de Munck, Frans Erdkamp, Willem M. Smit, K. Hoekman, Roy Lalisang, H. de Graaf, A.N.M. Wymenga, M. Polée, Harry Hollema, Marcel A.T.M. van Vugt, Michael Schaapveld, P.H.B. Willemse	2012	34
5	Phase II study of the combination cisplatin, etoposide, 5-fluorouracil and folinic acid in patients with advanced squamous cell carcinoma of the esophagus Anti-Cancer Drugs ·M. Polée, T.C. Kok, PD Siersema, HW Tilanus, T. A. W. Splinter, G. Stoter, Ate van der Gaast	2001	34
6	Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro) European Journal of Cancer ·Hielke J. Meulenbeld, Erik van Werkhoven, J.L. Coenen, G.J. Creemers, O. J. L. Loosveld, P.C. de Jong, Albert J. ten Tije, Sophie D. Fosså, M. Polée, Winald R. Gerritsen, Otilia Dalesio, Ronald de Wit	2012	31
7	Phase I study of a weekly schedule of a fixed dose of cisplatin and escalating doses of paclitaxel in patients with advanced oesophageal cancer European Journal of Cancer ·M. Polée, Jaap Verweij, Peter D. Siersema, H.W. Tilanus, Ted A.W. Splinter, G. Stoter, Ate van der Gaast	2002	15
8	Phase II study of neo-adjuvant chemotherapy with paclitaxel and cisplatin given every 2 weeks for patients with a resectable squamous cell carcinoma of the esophagus Annals of Oncology ·M. Polée, H.W. Tilanus, F. Eskens, Ronald Hoekstra, M.E.L. van der Burg, Peter D. Siersema, G. Stoter, Ate van der Gaast	2003	14
9	Catecholamines and Blood Glucose Control in Type 1 Diabetes Diabetic Medicine ·H. J. G. Bilo, Rijk O. B. Gans, M. Polée, Jan van der Maten, C. Popp‐Snijders, A. J. M. Donker	1991	3
10	Randomized phase III study of docetaxel with or without risedronate in patients with bone metastases from castration-resistant prostate cancer (CRPC): The Netherlands Prostate Study (NePro). Journal of Clinical Oncology ·Hielke J. Meulenbeld, Erik van Werkhoven, J.L. Coenen, Geert‐Jan Creemers, O. J. L. Loosveld, P.C. de Jong, Albert J. ten Tije, Sophie D. Fosså, M. Polée, Winald R. Gerritsen, Otilia Dalesio, Ronald de Wit	2011	3
11	Randomized, phase II study comparing cisplatin and high-dose 5-fluorouracil/leucovorin with paclitaxel and high-dose 5-fluorouracil/leucovorin in patients with advanced gastric cancer and adenocarcinomas of the gastroesophageal junction Journal of Clinical Oncology ·Margot Tesselaar, Saskia Luelmo, M. Polée, Aart van Bochove, Jannemieke Ouwerkerk, Hans Pruijt, H. P. Sleeboom	2008	3
12	Adding the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin in first line for stage IC-IV epithelial ovarian cancer: A randomized phase II study Journal of Clinical Oncology ·Anna K.L. Reyners, Willem M. Smit, Michael Schaapveld, K. Hoekman, F. Erdkamp, Robbert C. A. Lalisang, H. de Graaf, Machteld Wymenga, M. Polée, P.H.B. Willemse	2009	1
13	Randomised phase 3 study of S-1 versus capecitabine, with bevacizumab optional in both arms, in the first-line treatment of metastatic colorectal cancer (mCRC), the SALTO study of the Dutch Colorectal Cancer Group European Journal of Cancer ·Johannes J.M. Kwakman, Lieke H. J. Simkens, Johan M. van Rooijen, Agnès J. van de Wouw, O. J. L. Loosveld, G.J. Creemers, Mathijs P. Hendriks, Maartje Los, R J van Alphen, M. Polée, E.W. Muller, Ankie M.T. van der Velden, Theo van Voorthuizen, Miriam Koopman, L. Mol, Erik van Werkhoven, C.J.A. Punt	2017	1

About M. Polée

M. Polée is a scholar working on Pulmonary and Respiratory Medicine, Otorhinolaryngology, Oncology, Gastroenterology and Surgery, having authored 13 papers that have together received 330 indexed citations. Recurring topics across this work include Gastric Cancer Management and Outcomes (7 papers), Esophageal Cancer Research and Treatment (5 papers), Colorectal Cancer Treatments and Studies (3 papers), Esophageal and GI Pathology (3 papers), Prostate Cancer Treatment and Research (2 papers), Bone health and treatments (2 papers), Lung Cancer Treatments and Mutations (2 papers) and Estrogen and related hormone effects (2 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (216 citations), Surgery (192 citations), Oncology (115 citations), Cancer Research (32 citations) and Otorhinolaryngology (8 citations). M. Polée has collaborated with scholars based in Netherlands, United States and Norway. Frequent co-authors include G. Stoter, Ate van der Gaast, Peter D. Siersema, Ted A.W. Splinter, M.E.L. van der Burg, Ferry A.L.M. Eskens, T.C. Kok, H.W. Tilanus, Jaap Verweij and Wim C.J. Hop. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer, British Journal of Cancer and Anti-Cancer Drugs.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact